About Epiva Therapeutics
Epiva Therapeutics is a company based in Cambridge (United States) founded in 2015 was acquired by Evelo Biosciences in July 2016. Epiva Therapeutics operates in a competitive market with competitors including Biogen, Insitro, BridgeBio, ATAI and UCB, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Evelo Biosciences
(Jul 12, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Epiva Therapeutics
Detailed funding history for Epiva Therapeutics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Epiva Therapeutics
Epiva Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Evelo Biosciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapeutics for inflammatory diseases, COVID-19, and cancer are developed.
|
Locked | Locked | Locked |
Investor details for Epiva Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Epiva Therapeutics
Investment portfolio details for Epiva Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Epiva Therapeutics
Detailed financials for Epiva Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Epiva Therapeutics Comparisons
Peer comparison for Epiva Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Epiva Therapeutics
Epiva Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, Insitro, BridgeBio, ATAI and UCB, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Therapies for immunological and neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
Detailed competitors of Epiva Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Epiva Therapeutics
Complete news archive for Epiva Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Epiva Therapeutics
Epiva Therapeutics was founded in 2015.
Epiva Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Epiva Therapeutics was founded in 2015 in Cambridge, United States, as a microbiome-focused company originating from Flagship VentureLabs. Operations center on the development of therapeutics targeting autoimmune diseases linked to microbiome dysbiosis. The sector involves biotechnology applications in gut microbiome modulation to address immune dysregulation. Research and therapeutic innovation are conducted in the United States, with a emphasis on clinical translation for dysbiosis-associated conditions.
Epiva Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Epiva Therapeutics has 1 investor. Key investors include Evelo Biosciences.